{"groups":[{"description":"Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).","id":"FG000","title":"Pembrolizumab"},{"description":"Participants received placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"33"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"11"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"463"},{"groupId":"FG001","numSubjects":"454"}],"type":"Ongoing on trial follow up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"496"},{"groupId":"FG001","numSubjects":"498"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"488"},{"groupId":"FG001","numSubjects":"496"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Continuing Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"298"},{"groupId":"FG001","numSubjects":"365"}],"type":"Completed Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"190"},{"groupId":"FG001","numSubjects":"130"}],"type":"Discontinued Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completed Trial","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"496"},{"groupId":"FG001","numSubjects":"498"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 994 participants randomized in the study, 984 participants received study medication and were evaluable for safety analyses (Database cutoff date 14 Dec 2020)"}